Epsilon aminocaproic acid prevents bleeding in severely thrombocytopenic patients with hematological malignancies. (يفتح نافذة جديدة)

Antun AG, Gleason S, Arellano M, Langston AA, McLemore ML, Gaddh M, el Rassi F, Bernal-Mizrachi L, Galipeau J, Heffner LT Jr, Winton EF, Khoury HJ.

Source‎: Cancer 2013;119(21):3784-7.

مفهرسة‎: PubMed 23921838

DOI‎: 10.1002/cncr.28253

https://www.ncbi.nlm.nih.gov/pubmed/23921838 (يفتح نافذة جديدة)

Tranexamic acid for control of haemorrhage in acute promyelocytic leukaemia. (يفتح نافذة جديدة)

Avvisati G, ten Cate JW, Büller HR, Mandelli F.

Source‎: Lancet 1989;334(8655):122-4.

مفهرسة‎: PubMed 2567893

https://www.ncbi.nlm.nih.gov/pubmed/2567893 (يفتح نافذة جديدة)

Tranexamic acid therapy in acute myeloid leukemia: possible reduction of platelet transfusions. (يفتح نافذة جديدة)

Ben-Bassat I, Douer D, Ramot B.

Source‎: Eur J Haematol 1990;45(2):86-9.

مفهرسة‎: PubMed 2209824

https://www.ncbi.nlm.nih.gov/pubmed/2209824 (يفتح نافذة جديدة)

Fibrinolytic inhibitors for cancer-associated bleeding problems. (يفتح نافذة جديدة)

Dean A, Tuffin P.

Source‎: J Pain Symptom Manage 1997;13(1):20-4.

مفهرسة‎: PubMed 9029858

https://www.ncbi.nlm.nih.gov/pubmed/9029858 (يفتح نافذة جديدة)

Autologous stem-cell transplantation without hematopoietic support for the treatment of hematologic malignancies in Jehovah's Witnesses. (يفتح نافذة جديدة)

Ford PA, Grant SJ, Mick R, Keck G.

Source‎: J Clin Oncol 2015;33(15):1674-9.

مفهرسة‎: PubMed 25870085

DOI‎: 10.1200/JCO.2014.57.9912

https://www.ncbi.nlm.nih.gov/pubmed/25870085 (يفتح نافذة جديدة)

Anti-fibrinolytic therapy with aminocaproic acid for the control of bleeding in thrombocytopenic patients. (يفتح نافذة جديدة)

Garewal HS, Durie BG.

Source‎: Scand J Haematol 1985;35(5):497-500.

مفهرسة‎: PubMed 4089529

https://www.ncbi.nlm.nih.gov/pubmed/4089529 (يفتح نافذة جديدة)

Epsilon aminocaproic acid reduces transfusion requirements in patients with thrombocytopenic hemorrhage. (يفتح نافذة جديدة)

Kalmadi S, Tiu R, Lowe C, Jin T, Kalaycio M.

Source‎: Cancer 2006;107(1):136-40.

مفهرسة‎: PubMed 16708357

DOI‎: 10.1002/cncr.21958

https://www.ncbi.nlm.nih.gov/pubmed/16708357 (يفتح نافذة جديدة)

Aminocaproic acid use in hospitalized patients with hematological malignancy: a case series. (يفتح نافذة جديدة)

Marshall A, Li A, Drucker A, Dzik W.

Source‎: Hematol Oncol 2016;34(3):147-53.

مفهرسة‎: PubMed 25641349

DOI‎: 10.1002/hon.2189

https://www.ncbi.nlm.nih.gov/pubmed/25641349 (يفتح نافذة جديدة)

Tranexamic acid to treat life-threatening hemorrhage in prostate cancer associated disseminated intravascular coagulation with excessive fibrinolysis. (يفتح نافذة جديدة)

Prokopchuk-Gauk O, Brose K.

Source‎: Cureus 2015;7(12):e428.

مفهرسة‎: PubMed 26848417

DOI‎: 10.7759/cureus.428

https://www.ncbi.nlm.nih.gov/pubmed/26848417 (يفتح نافذة جديدة)

A controlled trial of tranexamic acid therapy for the reduction of bleeding during treatment of acute myeloid leukemia. (يفتح نافذة جديدة)

Shpilberg O, Blumenthal R, Sofer O, Katz Y, Chetrit A, Ramot B, Eldor A, Ben-Bassat I.

Source‎: Leuk Lymphoma 1995;19(1-2):141-4.

مفهرسة‎: PubMed 8574160

DOI‎: 10.3109/10428199509059668

https://www.ncbi.nlm.nih.gov/pubmed/8574160 (يفتح نافذة جديدة)

Acute promyelocytic leukaemia and acquired alpha-2-plasmin inhibitor deficiency: a retrospective look at the use of epsilon-aminocaproic acid (Amicar) in 30 patients. (يفتح نافذة جديدة)

Wassenaar T, Black J, Kahl B, Schwartz B, Longo W, Mosher D, Williams E.

Source‎: Hematol Oncol 2008;26(4):241-6.

مفهرسة‎: PubMed 18613223

DOI‎: 10.1002/hon.867

https://www.ncbi.nlm.nih.gov/pubmed/18613223 (يفتح نافذة جديدة)

Use of Novoseven for arsenic trioxide-induced bleeding in PML. (يفتح نافذة جديدة)

Alimoghaddam K, Ghavamzadeh A, Jahani M.

Source‎: Am J Hematol 2006;81(9):720.

مفهرسة‎: PubMed 16804937

DOI‎: 10.1002/ajh.20713

https://www.ncbi.nlm.nih.gov/pubmed/16804937 (يفتح نافذة جديدة)

Control of bleeding caused by thrombocytopenia associated with hematologic malignancy: an audit of the clinical use of recombinant activated Factor VII. (يفتح نافذة جديدة)

Brenner B, Hoffman R, Balashov D, Shutluko E, Čulić SD, Nizamoutdinova E.

Source‎: Clin Appl Thromb Hemost 2005;11(4):401-10.

مفهرسة‎: PubMed 16244765

https://www.ncbi.nlm.nih.gov/pubmed/16244765 (يفتح نافذة جديدة)

The off-label use of recombinant FVIIa in the treatment of a patient with T-cell non-Hodgkin lymphoma who developed intra-abdominal and intra-pleural hemorrhages followed by high-dose methotreaxate therapy. (يفتح نافذة جديدة)

Erduran E, Bahadir A, Mutlu M.

Source‎: Eur J Clin Med Oncol 2011;3(5):1-4.

مفهرسة‎: EMBASE 2012295551

https://www.worldcat.org/title/european-journal-of-clinical-medical-oncology/oclc/645421559&referer=brief_results (يفتح نافذة جديدة)

The potential role of recombinant activated FVII in the management of critical hemato-oncological bleeding: a systematic review. (يفتح نافذة جديدة)

Franchini M, Veneri D, Lippi G.

Source‎: Bone Marrow Transplant 2007;39(12):729-35.

مفهرسة‎: PubMed 17417659

DOI‎: 10.1038/sj.bmt.1705670

https://www.ncbi.nlm.nih.gov/pubmed/17417659 (يفتح نافذة جديدة)

Effective hemostasis with rFVIIa treatment in two patients with severe thrombocytopenia and life-threatening hemorrhage. (يفتح نافذة جديدة)

Gerotziafas GT, Zervas C, Gavrielidis G, Tokmaktsis A, Hatjiharissi E, Papaioannou M, Lazaridou A, Constantinou N, Samama MM, Christakis J.

Source‎: Am J Hematol 2002;69(3):219-22.

مفهرسة‎: PubMed 11891811

https://www.ncbi.nlm.nih.gov/pubmed/11891811 (يفتح نافذة جديدة)

Use of recombinant activated factor VII in a Jehovah's Witness patient. (يفتح نافذة جديدة)

Hsieh A, Cheong I.

Source‎: Am J Emerg Med 2007;25(9):1085.e1-2.

مفهرسة‎: PubMed 18022514

DOI‎: 10.1016/j.ajem.2007.03.007

https://www.ncbi.nlm.nih.gov/pubmed/18022514 (يفتح نافذة جديدة)

Clinical experience with recombinant factor VIIa in patients with thrombocytopenia. (يفتح نافذة جديدة)

Kristensen J, Killander A, Hippe E, Helleberg C, Ellegard J, Holm M, Kutti J, Mellqvist UH, Johansson JE, Glazer S, Hedner U.

Source‎: Haemostasis 1996;26 Suppl 1:159-64.

مفهرسة‎: PubMed 8904193

https://www.ncbi.nlm.nih.gov/pubmed/8904193 (يفتح نافذة جديدة)

Successful treatment of severe gastrointestinal bleeding after chemotherapy in acute myeloblastic leukemia with recombinant activated factor VII: report on one case and review of other uses in acute leukemias. (يفتح نافذة جديدة)

Pamuk GE, Taşçi M, Oztürk E, Demir M.

Source‎: Med Oncol 2010;27(1):16-9.

مفهرسة‎: PubMed 19137431

DOI‎: 10.1007/s12032-008-9163-y

https://www.ncbi.nlm.nih.gov/pubmed/19137431 (يفتح نافذة جديدة)

Recombinant factor VIIa for bleeding in refractory thrombocytopenia. (يفتح نافذة جديدة)

Vidarsson B, Önundarson PT.

Source‎: Thromb Haemost 2000;83(4):634-5.

مفهرسة‎: PubMed 10780334

https://www.ncbi.nlm.nih.gov/pubmed/10780334 (يفتح نافذة جديدة)

Effective treatment of life-threatening bleeding with recombinant activated factor VII in a patient with acute promyelocytic leukaemia. (يفتح نافذة جديدة)

Zver S, Andoljšek D, Černelč P.

Source‎: Eur J Haematol 2004;72(6):455-6.

مفهرسة‎: PubMed 15128428

DOI‎: 10.1111/j.1600-0609.2004.00237.x

https://www.ncbi.nlm.nih.gov/pubmed/15128428 (يفتح نافذة جديدة)

Management of bleeding complications of hematologic malignancies. (يفتح نافذة جديدة)

Green D.

Source‎: Semin Thromb Hemost 2007;33(4):427-34.

مفهرسة‎: PubMed 17525900

DOI‎: 10.1055/s-2007-976178

https://www.ncbi.nlm.nih.gov/pubmed/17525900 (يفتح نافذة جديدة)

Vitamin K deficiency in cancer patients referred to a hospital palliative care team with bleeding and the impact of vitamin K replacement on laboratory indicators of vitamin K status. (يفتح نافذة جديدة)

Harrington DJ, Booth L, Dando N, Cottingham L, Beynon T.

Source‎: Int J Lab Hematol 2013;35(4):457-9.

مفهرسة‎: PubMed 23216984

DOI‎: 10.1111/ijlh.12035

https://www.ncbi.nlm.nih.gov/pubmed/23216984 (يفتح نافذة جديدة)

Management of bleeding in patients with advanced cancer. (يفتح نافذة جديدة)

Pereira J, Phan T.

Source‎: Oncologist 2004;9(5):561-70.

مفهرسة‎: PubMed 15477642

DOI‎: 10.1634/theoncologist.9-5-561

https://www.ncbi.nlm.nih.gov/pubmed/15477642 (يفتح نافذة جديدة)

Pilot study on the safety and efficacy of desmopressin for the treatment or prevention of bleeding in patients with hematologic malignancies. (يفتح نافذة جديدة)

Castaman G, Bona ED, Schiavotto C, Trentin L, D'Emilio A, Rodeghiero F.

Source‎: Haematologica 1997;82(5):584-7.

مفهرسة‎: PubMed 9407726

https://www.ncbi.nlm.nih.gov/pubmed/9407726 (يفتح نافذة جديدة)

Desmopressin and other synthetic vasopressin analogues in cancer treatment. (يفتح نافذة جديدة)

Gomez DE, Ripoll GV, Girón S, Alonso DF.

Source‎: Bull Cancer 2006;93(2):E7-12.

مفهرسة‎: PubMed 16517412

https://www.ncbi.nlm.nih.gov/pubmed/16517412 (يفتح نافذة جديدة)